PortfoliosLab logoPortfoliosLab logo
RZLT vs. CRBP
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

RZLT vs. CRBP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rezolute, Inc. (RZLT) and Corbus Pharmaceuticals Holdings, Inc. (CRBP). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, RZLT achieves a 101.27% return, which is significantly higher than CRBP's 18.92% return. Both investments have delivered pretty close results over the past 10 years, with RZLT having a -20.14% annualized return and CRBP not far behind at -20.50%.


RZLT

1D
-7.41%
1M
18.75%
6M
80.61%
YTD
101.27%
1Y
-9.70%
3Y*
31.27%
5Y*
-15.17%
10Y*
-20.14%

CRBP

1D
0.21%
1M
18.19%
6M
16.49%
YTD
18.92%
1Y
17.05%
3Y*
7.01%
5Y*
-28.44%
10Y*
-20.50%
*Multi-year figures are annualized to reflect compound growth (CAGR)

RZLT vs. CRBP - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
RZLT
Rezolute, Inc.
101.27%-51.84%393.70%-52.05%-56.69%-60.13%108.52%27.78%-89.83%-11.50%
CRBP
Corbus Pharmaceuticals Holdings, Inc.
18.92%-31.02%95.36%82.20%-82.05%-50.74%-77.11%-6.51%-17.75%-15.98%

Correlation

The correlation between RZLT and CRBP is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.25

Correlation (3Y)
Calculated over the trailing 3-year period

0.23

Correlation (5Y)
Calculated over the trailing 5-year period

0.17

Correlation (10Y)
Calculated over the trailing 10-year period

0.09

Correlation (All Time)
Calculated using the full available price history since Nov 11, 2014

0.07

The correlation between RZLT and CRBP shifts across timeframes, from 0.07 (all time) to 0.25 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

RZLT:

$457.39M

CRBP:

$121.34M

EPS

RZLT:

-$0.79

CRBP:

-$5.72

PB Ratio

RZLT:

4.23

CRBP:

1.43

Total Revenue (TTM)

RZLT:

$0.00

CRBP:

$0.00

Gross Profit (TTM)

RZLT:

-$15.00K

CRBP:

-$149.00K

EBITDA (TTM)

RZLT:

-$67.00M

CRBP:

-$61.36M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

RZLT vs. CRBP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RZLT
RZLT Risk / Return Rank: 5656
Overall Rank
RZLT Sharpe Ratio Rank: 4242
Sharpe Ratio Rank
RZLT Sortino Ratio Rank: 7171
Sortino Ratio Rank
RZLT Omega Ratio Rank: 8686
Omega Ratio Rank
RZLT Calmar Ratio Rank: 4242
Calmar Ratio Rank
RZLT Martin Ratio Rank: 4242
Martin Ratio Rank

CRBP
CRBP Risk / Return Rank: 5454
Overall Rank
CRBP Sharpe Ratio Rank: 5353
Sharpe Ratio Rank
CRBP Sortino Ratio Rank: 5656
Sortino Ratio Rank
CRBP Omega Ratio Rank: 5858
Omega Ratio Rank
CRBP Calmar Ratio Rank: 5252
Calmar Ratio Rank
CRBP Martin Ratio Rank: 5050
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RZLT vs. CRBP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Rezolute, Inc. (RZLT) and Corbus Pharmaceuticals Holdings, Inc. (CRBP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


RZLTCRBPDifference
Sharpe ratioReturn per unit of total volatility

-0.28

Sortino ratioReturn per unit of downside risk

+0.67

Omega ratioGain probability vs. loss probability

1.31

1.12

+0.19

Calmar ratioReturn relative to maximum drawdown

-0.11

0.26

-0.37

Martin ratioReturn relative to average drawdown

-0.18

0.36

-0.54

RZLT vs. CRBP - Sharpe Ratio Comparison

The current RZLT Sharpe Ratio is -0.08, which is lower than the CRBP Sharpe Ratio of 0.20. The chart below compares the historical Sharpe Ratios of RZLT and CRBP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

RZLT vs. CRBP - Drawdown Comparison

The maximum RZLT drawdown since its inception was -99.63%, roughly equal to the maximum CRBP drawdown of -99.31%. Use the drawdown chart below to compare losses from any high point for RZLT and CRBP.


Loading charts...

Drawdown Indicators


RZLTCRBPDifference

Max Drawdown

Largest peak-to-trough decline

-99.63%

-99.31%

-0.32%

Max Drawdown (1Y)

Largest decline over 1 year

-87.20%

-61.88%

-25.32%

Max Drawdown (3Y)

Largest decline over 3 years

-87.20%

-92.01%

+4.81%

Max Drawdown (5Y)

Largest decline over 5 years

-93.50%

-95.46%

+1.96%

Max Drawdown (10Y)

Largest decline over 10 years

-99.16%

-99.31%

+0.15%

Current Drawdown

Current decline from peak

-97.63%

-96.88%

-0.75%

Average Drawdown

Average peak-to-trough decline

-87.08%

-66.25%

-20.83%

Ulcer Index

Depth and duration of drawdowns from previous peaks

53.14%

43.50%

+9.64%

Volatility

RZLT vs. CRBP - Volatility Comparison

Rezolute, Inc. (RZLT) has a higher volatility of 17.16% compared to Corbus Pharmaceuticals Holdings, Inc. (CRBP) at 13.19%. This indicates that RZLT's price experiences larger fluctuations and is considered to be riskier than CRBP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


RZLTCRBPDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.16%

13.19%

+3.97%

Volatility (6M)

Calculated over the trailing 6-month period

57.18%

60.65%

-3.47%

Volatility (1Y)

Calculated over the trailing 1-year period

125.90%

79.15%

+46.75%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

94.76%

159.12%

-64.36%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

160.42%

129.05%

+31.37%

Dividends

RZLT vs. CRBP - Dividend Comparison

Neither RZLT nor CRBP has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

RZLT vs. CRBP - Financials Comparison

This section allows you to compare key financial metrics between Rezolute, Inc. and Corbus Pharmaceuticals Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00K40.00K60.00K80.00K100.00K120.00K140.00KJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober202600
(RZLT) Total Revenue
(CRBP) Total Revenue
Values in USD except per share items

Frequently Asked Questions


RZLT and CRBP have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

RZLT has higher volatility (17.16%) compared to CRBP (13.19%). In terms of maximum drawdown, RZLT dropped -99.63% vs CRBP's -99.31%.

CRBP currently has the higher Sharpe Ratio (0.20 vs -0.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for RZLT and CRBP

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer